Marsh USA Inc.: Challenges of Pandemic Insurance in a COVID-19 World Custom Case Solution & Analysis

Evidence Brief: Marsh USA Inc. and the Pandemic Insurance Gap

1. Financial Metrics

• Marsh & McLennan (MMC) Revenue: 17.2 billion USD in 2019.
• Global Insurance Capital: Total global property and casualty insurance capital estimated at 2 trillion USD.
• Economic Loss Estimates: US small business losses estimated between 250 billion and 430 billion USD per month during COVID-19 lockdowns.
• PathogenRX Capacity: Maximum limit of 100 million USD per client prior to the 2020 pandemic.
• Market Cap Gap: The ratio of potential pandemic economic loss to total industry capital exceeds 1:1 monthly, indicating a systemic insolvency risk if fully insured by the private market.

2. Operational Facts

• Product Structure: PathogenRX is a parametric insurance product launched in 2018. It utilizes data from Metabiota and insurance capacity from Munich Re.
• Trigger Mechanism: Payouts are triggered by specific events, such as a World Health Organization declaration of a Public Health Emergency of International Concern (PHEIC), rather than proof of physical damage.
• Traditional Policy Limits: Standard Business Interruption (BI) policies require physical loss or damage to property, a requirement that most courts upheld as not met by viral presence.
• Geographic Reach: Marsh operates in over 130 countries, with significant concentration in the US and Canadian markets.

3. Stakeholder Positions

• John Doyle (CEO, Marsh): Advocates for a public-private partnership to handle systemic risks that exceed private market capacity.
• Martin South (President, US and Canada): Focuses on client advisory and the immediate need for certainty in coverage triggers.
• Munich Re: Provided initial capacity for PathogenRX but faces significant capital constraints for pandemic perils post-2020.
• Metabiota: Provides the epidemic modeling and sentiment tracking data used to define parametric triggers.
• US Congress: Evaluates the Pandemic Risk Insurance Act (PRIA), modeled after the Terrorism Risk Insurance Act (TRIA).

4. Information Gaps

• Renewal Pricing: The case does not specify the exact premium increases for PathogenRX following the COVID-19 outbreak.
• Client Adoption Rates: Specific numbers on how many clients purchased PathogenRX between 2018 and 2020 are missing.
• Reinsurer Appetite: The long-term willingness of reinsurers other than Munich Re to back parametric pandemic products is not detailed.

Strategic Analysis: Addressing Systemic Market Failure

1. Core Strategic Question

• Can Marsh maintain its role as a risk transfer leader when the underlying peril is uninsurable by the private market alone?
• How should Marsh balance product innovation (parametric) with legislative advocacy (PRIA) to close the protection gap?

2. Structural Analysis

The pandemic risk landscape reveals a fundamental market failure. Applying a supply-demand lens shows that while demand for pandemic coverage is at an all-time high, supply has effectively vanished because the risk is non-diversifiable. Unlike fire or localized floods, a pandemic affects all policyholders simultaneously, breaking the law of large numbers that insurance relies upon.

Supplier power (reinsurers) is absolute; they are exiting the market or inserting broad communicable disease exclusions. Buyer power is high in terms of political influence but low in terms of market choice. Marsh sits in the middle, facing a threat of obsolescence if it cannot facilitate a functional market.

3. Strategic Options

4. Preliminary Recommendation

Marsh must prioritize the Legislative Lead (PRIA) strategy. The scale of pandemic loss (trillions) vs. insurance capital (billions) makes any private-only solution a niche product. Marsh should act as the primary architect of the PRIA framework, ensuring the broker role remains central to the distribution of a government-backed product. This secures the long-term viability of the industry while positioning Marsh as an indispensable advisor to both the state and the private sector.

Implementation Roadmap: Building the Federal Backstop

1. Critical Path

• Month 1-2: Coalition Formation. Align the American Property Casualty Insurance Association (APCIA) and other major brokers to present a unified industry front to Congress.
• Month 3-5: Technical Design. Collaborate with Metabiota to define the data standards that the government will use to trigger the federal backstop, ensuring consistency across the industry.
• Month 6-12: Legislative Lobbying. Execute a targeted campaign to pass PRIA, emphasizing economic stability and the prevention of future taxpayer-funded bailouts.
• Month 12+: Product Integration. Launch new hybrid products that combine private parametric layers with the federal excess-of-loss backstop.

2. Key Constraints

• Political Gridlock: Fiscal conservatives may oppose a new federal insurance mandate or backstop, viewing it as an industry bailout.
• Actuarial Uncertainty: The lack of historical data for modern globalized pandemics makes pricing the private layer of a public-private partnership extremely difficult.
• Carrier Participation: If the federal backstop requires high mandatory participation from private carriers, some may choose to exit certain lines of business entirely to avoid the exposure.

3. Risk-Adjusted Implementation Strategy

The strategy assumes that the government is the only entity with a balance sheet large enough to act as the insurer of last resort. To mitigate the risk of legislative failure, Marsh must simultaneously develop the Captive Advisory workstream. This provides a fallback for large corporate clients to fund their own risks if PRIA fails to pass. The implementation must move away from selling traditional indemnity and toward selling data-driven risk management services where Marsh earns fees rather than just commissions.

Executive Review and BLUF

1. BLUF

Marsh must pivot from a traditional brokerage model to a systemic risk architect. The 2 trillion USD in global insurance capital is insufficient to cover a 1 trillion USD monthly economic loss. Private pandemic insurance is currently a failed product. The only viable path forward is to lead the creation of a federal backstop (PRIA). This ensures Marsh remains the essential intermediary between government-backed capital and corporate risk. Failure to secure a public-private solution will lead to a permanent contraction in the business interruption market and a significant loss of brokerage revenue.

2. Dangerous Assumption

The analysis assumes that the US government will view pandemic risk as a permanent, backstop-worthy peril similar to terrorism. There is a material risk that legislators will instead view COVID-19 as a once-in-a-century event, preferring ad-hoc stimulus packages over a structured, permanent insurance framework. If this assumption fails, the industry remains exposed to future systemic shocks without a safety net.

3. Unaddressed Risks

• Moral Hazard: A federal backstop may discourage businesses from investing in their own operational resilience, as they expect government-guaranteed insurance to cover future lockdowns.
• Basis Risk in Parametrics: If PathogenRX triggers on a WHO declaration but a local government does not mandate a lockdown, or vice versa, clients will face massive losses without a payout, leading to significant reputational damage for Marsh.

4. Unconsidered Alternative

The team has not fully explored the potential for a Capital Markets solution. Catastrophe bonds for pandemics could tap into the 100 trillion USD global capital market, providing a much larger pool of liquidity than the insurance industry alone. While expensive, this would bypass the political uncertainty of a federal backstop.

5. Verdict

APPROVED FOR LEADERSHIP REVIEW